Abstract
M yasthenia gravis is a potentially serious but treatable autoimmune disorder characterized by weakness and fatigability of the voluntary muscles caused by auto-antibodies against nicotinic acetylcholine receptor (AChR) on the postsynaptic membrane at the neuromuscular junction.1,2 Its prevalence has been reported as 2–7/10,000 population in the UK and around 1.5/10,000 in central and western Virginia. Approximately 1% of patients are children.1 Although many deviations may occur, most immunemediated childhood myasthenia gravis can be divided into three categories: neonatal transient, neonatal persistent, and juvenile myasthenia gravis.1 Myasthenia gravis used to be a very disabling and often fatal disease (hence, the name gravis) in the past. However, significant advances in its diagnosis and treatment have dramatically improve the prognosis and nearly all patients are now able to lead full, productive lives. 2,3
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
